A case links cannabis withdrawal relief to rapid symptom resolution

Gabapentin for the Management of Suspected Cannabis Withdrawal in a Pregnant Patient With a History of Cannabinoid Hyperemesis Syndrome: A Case Report.

Case reports in obstetrics and gynecology • • Highly Relevant
🤖

AI Summary

Cannabinoid hyperemesis syndrome (CHS) can resemble severe pregnancy-related vomiting, making diagnosis difficult. This case involved a 24-year-old pregnant patient at 20 weeks’ gestation who had recurrent nausea, vomiting, labile hypertension, a previous CHS hospitalization, and cannabis use disorder. Her recent reduction in cannabis use raised concern that cannabis withdrawal was contributing to her symptoms.

After consultation with Addiction Medicine, clinicians used gabapentin off-label. Symptoms resolved and blood pressure normalized within 24 hours, with no apparent maternal or fetal complications reported. However, this is a single case report—not evidence that gabapentin is broadly effective or proven safe during pregnancy. The report’s main practical message is that healthcare professionals should ask about cannabis use, recent reduction or cessation, and withdrawal when evaluating severe or persistent vomiting in pregnancy.

💡 Key Findings

1
In a pregnant patient with prior cannabinoid hyperemesis syndrome and suspected cannabis withdrawal, off-label gabapentin was followed by resolution of symptoms and normalized blood pressure within 24 hours.
Moderate
45%
2
The case emphasizes that clinicians should screen pregnant patients with severe or refractory vomiting for cannabis use, recent reduction or cessation, and withdrawal symptoms.
Moderate
50%
3
Short-term gabapentin use was reported without apparent maternal or fetal complications, but evidence remains limited because this is a single case report.
Moderate
45%

📄 Original Abstract

Cannabinoid hyperemesis syndrome (CHS) is a rare but increasingly recognized condition among chronic cannabis users, characterized by cyclic nausea, vomiting, and relief with hot bathing. During pregnancy, CHS may mimic hyperemesis gravidarum (HG), complicating diagnosis and management. We report the case of a 24-year-old pregnant patient who presented at 20 weeks' gestation with recurrent nausea, vomiting, and labile hypertension. Investigations ruled out preeclampsia and secondary causes of hypertension. She met DSM-5 criteria for cannabis use disorder, had a prior hospitalization for CHS, and had recently reduced her cannabis use, raising concern for withdrawal as a contributing factor to her presentation. Gabapentin was initiated off-label after an Addiction Medicine consultation, resulting in resolution of symptoms and normalization of blood pressure within 24 h. To our knowledge, this is the first reported use of gabapentin in a pregnant patient with a history of CHS and suspected cannabis withdrawal. This report highlights the importance of screening for cannabis use, recent reduction or cessation, and withdrawal symptoms in pregnant patients presenting with severe or refractory hyperemesis. In this case, short-term off-label gabapentin use led to rapid symptom resolution without apparent maternal or fetal complications, suggesting that it may be relatively safe in this population, although data remain limited.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.